Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy

• 1. Sign an informed consent form;
• 2. HBsAg (+), and the course of the disease exceeds six months;
• 3. Age range from 16 to 70 years old;
• 4. Female participants of childbearing age who had a negative pregnancy test before the trial and were able to take effective contraceptive measures;
• 5. During the treatment period, within six months after the end of treatment, the patients agrees to use contraception

Exclusion Criteria:

• 1. Patients with a known history of allergy to Peg-IFNα and NAs;
• 2. Co-infection with other virus such as HAV, HCV, HDV, HEV, HIV, etc;
• 3. Patients with liver cirrhosis or a Child Pugh score of 7 or above;
• 4. History or evidence of liver disease caused by other factors (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.);
• 5. Pregnant or lactating women; Have a history of alcohol or drug abuse within the year prior to the trial enrollment screening;
• 6. Neutrophil count\<1.5 × 109/L or hemoglobin\<100g/L or platelet count\<80 × 109/L; During the trial enrollment screening, serum creatinine was higher than the upper normal limit;
• 7. A history of severe diseases in important organs and tissues such as the heart, brain, kidneys, retina, and muscles;
• 8. Having a history of mental illness or a family history of mental illness, or a Hamilton Depression Scale score greater than 7 points;
• 9. History of endocrine system or autoimmune diseases, such as thyroid disease, diabetes, systemic lupus erythematosus, sarcoidosis, autoimmune thrombocytopenic purpura, etc;
• 10. History of malignant tumors;
• 11. During the trial enrollment screening, suspicious liver malignant tumors were detected by ultrasound, or AFP was greater than 100ng/mL or AFP cannot remain stable within 3 months prior to the experiment;
• 12. Has a history of important organ transplantation;
• 13. Other diseases that researchers believe are not suitable for inclusion.